TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 5c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.28), $0.05 better than the analyst estimate of ($0.33).

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Morgan Stanley Starts eMemory Technology Inc (3529:TT) at Overweight
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform